Table 1.

Sensitivity and specificity of purified and electroeluted antigens with human sera

Purified and electroeluted antigens (kDa)	Sensitivity to active VL patients in % (n/N)	Sensitivity to 1-month treated VL patients in % (n/N)	Sensitivity to 6-month follow-up patients in % (n/N)	Specificity to other diseases in % (n’/N)	Specificity to healthy samples in % (n’/N)
LAg	100 (13/13)	84.16 (11/13)	0 (0/13)	100 (13/13)	100 (13/13)
SLA	100 (13/13)	100 (13/13)	7.69 (1/13)	100 (13/13)	100 (13/13)
31	100 (23/23)	60 (14/23)	26.08 (6/23)	39.1 (9/23)	100 (23/23)
34	100 (23/23)	73.91 (17/23)	13.04 (3/23)	100 (23/23)	100 (23/23)
36	100 (23/23)	69.56 (16/23)	78.26 (18/23)	40 (8/23)	100 (23/23)
45	100 (23/23)	100 (23/23)	60.86 (14/23)	30.43 (7/23)	60.86 (14/23)
51	100 (23/23)	91.30 (21/23)	30.43 (7/23)	100 (23/23)	100 (23/23)
63	100 (23/23)	47.82 (11/23)	4.34 (1/23)	91.30 (21/23)	95.65 (22/23)
72	100 (23/23)	39.1 (9/23)	0 (0/23)	65.21 (15/23)	73.91 (17/23)
91	100 (23/23)	8.69 (2/23)	0 (0/23)	95.75 (22/23)	91.30 (21/23)
97	100 (23/23)	78.23 (18/23)	86.95 (20/23)	95.75 (22/23)	100 (23/23)

Abbreviations: n, no. of positive samples in each group; N, total no. of samples tested in each group; n’, no. of negative samples in each group